US regulators inspect Dr Reddy’s, other Indian pharma majors

Signs are seen outside the headquarters of the Food and Drug Administration (FDA) in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire license rights

HYDERABAD, Dec 5 (Reuters) - The U.S. Food and Drug Administration is inspecting Dr. Reddy's (REDY.NS) research and development center in the southern Indian city of Hyderabad, the pharmaceutical company said Tuesday.

"We confirm the initiation of a USFDA inspection at our R&D (Integrated Product Development Organization or IPDO) center," a Reddy spokesperson told Reuters.

A Laurus Labs unit (SONG.NS) The Laurus Synthesis subsidiary in Vizag, a city in the southern state of Andhra Pradesh, is also under inspection by the US drug regulator, according to a source familiar with the matter.

Sun Pharma Rivals (DOM.NS) Dadra and Torrent Pharmaceuticals Ltd facilities. (TORP.NS) The oncology unit is also undergoing FDA inspections, CNBC-TV18 reported.

Sun Pharma, Laurus and Torrent did not immediately respond to Reuters requests for comment.

Torrent Pharma closed down 1.6% following the news, while Laurus Labs closed down 0.9%. Sun Pharma and Dr. Reddy's closed up 0.7% and 0.4% respectively.

Reporting by Rishika Sadam in Hyderabad, Kashish Tandon in Bengaluru; Editing by Sonia Cheema and Sohini Goswami

Our standards: The Thomson Reuters Trust Principles.

Acquire license rightsopen a new tab
Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *